In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders' Opinions and Clinical Data Indicate that Tivopath Has Efficacy and

  In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders' Opinions and
Clinical Data Indicate that Tivopath Has Efficacy and Tolerability Advantages
                        Over Currently Used Therapies

Improved Progression-Free Survival is One of the Greatest Unmet Needs in RCC,
According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., March 26, 2013

BURLINGTON, Mass., March 26, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that surveyed U.S. and European oncologists agree
that a therapy's effect on overall survival and disease progression are the
attributes that most influences their decisions regarding prescribing in
advanced renal cell carcinoma. Clinical data and the opinions of interviewed
thought leaders indicate that Aveo Oncology/Astellas Pharma/Kyowa Hakko
Kirin's Tivopath has advantages over currently used therapies on disease

(Logo: )

According to the DecisionBase 2013 report entitled A Promising Immunotherapy
Is on the Horizon. What Attributes Does It Need to Trump the Angiogenesis and
mTOR Inhibitors?, surveyed U.S. oncologists indicate that they would prescribe
Tivopath to 30 percent of their pretreated advanced renal cell carcinoma
patients. However, owing to its Phase III clinical trial design and delay in
reaching the already crowded market behind Pfizer's Inlyta, Decision Resources
forecasts that Tivopath will earn a more modest 11 percent patient share in
the U.S. pretreated advanced renal cell carcinoma market by 2021.

The report also finds that surveyed oncologists and managed care organization
(MCO) pharmacy directors indicate that improved overall survival and
progression-free survival are the greatest unmet needs in pretreated advanced
renal cell carcinoma. Interviewed thought leaders are optimistic that
Bristol-Myers Squibb's nivolumab has the potential to improve overall survival
and at least in part address this unmet need.

"The MCO pharmacy directors we surveyed are particularly receptive to new
pretreated advanced renal cell carcinoma therapies that offer improvements in
median overall survival over currently available therapies," said Decision
Resources Analyst Samuel Mentzer. "While some emerging therapies, such as
nivolumab, hold promise, we do not expect any will match the clinical
improvement over current therapies that surveyed U.S. payers indicated would
be necessary for widespread inclusion on MCO formularies."

About Decision Resources
Decision Resources ( is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Contact: Decision Resources, Christopher Comfort, +1-781-993-2597,
Press spacebar to pause and continue. Press esc to stop.